Business Description
Aligos Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US01626L1052
Share Class Description:
STU:5WK0: Ordinary SharesDescription
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.2 | |||||
| Equity-to-Asset | 0.57 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.1 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -8.27 | |||||
| Beneish M-Score | -3.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 48.1 | |||||
| 3-Year EPS without NRI Growth Rate | 50 | |||||
| 3-Year FCF Growth Rate | 45.6 | |||||
| 3-Year Book Growth Rate | -41.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 23.88 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 87.36 | |||||
| 9-Day RSI | 90.12 | |||||
| 14-Day RSI | 91.46 | |||||
| 6-1 Month Momentum % | 22.51 | |||||
| 12-1 Month Momentum % | -12.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.81 | |||||
| Quick Ratio | 3.81 | |||||
| Cash Ratio | 3.58 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -27.1 | |||||
| Shareholder Yield % | 1.44 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1577.26 | |||||
| Net Margin % | -1283.19 | |||||
| FCF Margin % | -1420.02 | |||||
| ROE % | -118.75 | |||||
| ROA % | -68.4 | |||||
| ROIC % | -496.24 | |||||
| ROC (Joel Greenblatt) % | -1023.77 | |||||
| ROCE % | -104.46 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 27.68 | |||||
| PB Ratio | 2.61 | |||||
| Price-to-Tangible-Book | 2.61 | |||||
| EV-to-EBIT | -0.78 | |||||
| EV-to-EBITDA | -0.8 | |||||
| EV-to-Revenue | 12.27 | |||||
| EV-to-FCF | -0.86 | |||||
| Price-to-Net-Current-Asset-Value | 3.15 | |||||
| Price-to-Net-Cash | 3.57 | |||||
| Earnings Yield (Greenblatt) % | -128.21 | |||||
| FCF Yield % | -60.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aligos Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 5.494 | ||
| EPS (TTM) (€) | -15.644 | ||
| Beta | 1.95 | ||
| Volatility % | 82.02 | ||
| 14-Day RSI | 91.46 | ||
| 14-Day ATR (€) | 1.379119 | ||
| 20-Day SMA (€) | 24.11 | ||
| 12-1 Month Momentum % | -12.52 | ||
| 52-Week Range (€) | 8.0625 - 36.2 | ||
| Shares Outstanding (Mil) | 3.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aligos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aligos Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aligos Therapeutics Inc Frequently Asked Questions
What is Aligos Therapeutics Inc(STU:5WK0)'s stock price today?
The current price of STU:5WK0 is €34.00. The 52 week high of STU:5WK0 is €36.20 and 52 week low is €8.06.
When is next earnings date of Aligos Therapeutics Inc(STU:5WK0)?
The next earnings date of Aligos Therapeutics Inc(STU:5WK0) is 2025-03-12 Est..
Does Aligos Therapeutics Inc(STU:5WK0) pay dividends? If so, how much?
Aligos Therapeutics Inc(STU:5WK0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers